CollPlant
A regenerative and aesthetic medicine company developing innovative 3D bioprinting technologies and products based on proprietary plant-derived recombinant human collagen (rhCollagen) for tissue regeneration, organ manufacturing, and medical aesthetics.
- CEO / Founder
- Yehiel Tal
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $30.6M
- Latest Round
- Registered Direct Offering (Feb 2026)
- Key Investors
- Pontifax, Docor International, Alpha Capital Partners, Ami Sagy
Technology & Products
Key Products
["Collink.3D® BioInks - First and only human collagen-based bioink line for 3D bioprinting","BioFlex - Ready-to-print rhCollagen-based kit for Digital Light Processing (DLP) bioprinting applications (launched Feb 2026)","Regenerative Breast Implants - 3D bioprinted commercial-sized (200cc) implants","Photocurable Dermal Fillers - Light-activated rhCollagen aesthetic treatments","rhCollagen Raw Material - Pure recombinant human collagen for biomedical applications","Tissue/Organ-on-a-Chip Systems - Alternative to animal testing models","Vergenix™ STR - Tendon-repair product combining rhCollagen with platelet-rich plasma (PRP)"]
Technological Advantage
Proprietary plant-based recombinant human Type I collagen production technology that provides mass-production scalability, batch-to-batch consistency, high purity, zero risk of human pathogen transmission, elimination of immune response compared to animal-derived collagen, and full biocompatibility with human tissue - enabling revolutionary applications in 3D bioprinting and regenerative medicine that were previously impossible.
Differentiation
Value Proposition
Only commercially viable technology for mass production of plant-derived recombinant human Type I collagen (rhCollagen) that is identical to human body-produced collagen, eliminating immune response risks while providing scalable, high-purity, and consistent collagen for 3D bioprinting of tissues/organs and regenerative medicine applications.
How They Differentiate
Only company producing recombinant human Type I collagen (rhCollagen) from genetically engineered tobacco plants - identical to human body collagen with zero immune response risk, full biocompatibility, and scalable mass production unlike animal-derived collagen competitors
Market & Competition
Target Customers
Medical device manufacturers, pharmaceutical companies, research institutions, aesthetic medicine practitioners, tissue engineering companies, and organizations seeking alternatives to animal testing in drug development and safety studies
Industry Verticals
["Regenerative Medicine","3D Bioprinting","Medical Aesthetics","Tissue Engineering","Medical Devices","Pharmaceutical Research","Orthopedics","Advanced Wound Care"]
Competitors
CELLINK (BICO Group); 3D Systems (Allevi); Advanced BioMatrix
Growth & Milestones
Growth Metrics
Public company (NASDAQ: CLGN) since 2018; early revenue stage with $515K revenue in 2024 and $2M AbbVie milestone payment in Feb 2025; expanding North American commercial operations
Major Milestones
["NASDAQ listing commenced January 31, 2018","Strategic partnership with AbbVie for medical aesthetics (ongoing with $2M milestone payment Feb 2025)","Collaboration with Stratasys for regenerative breast implants using P3 technology","License agreement with United Therapeutics for 3D bioprinted lungs (Oct 2018)","Mayo Clinic validation of fully humanized 3D bioprinted skin model (Oct 2025)","Launch of BioFlex DLP bioprinting kit (Feb 2026)"]
Notable Customers
AbbVie (Allergan Aesthetics); United Therapeutics; Stratasys; Mayo Clinic; STEMCELL Technologies